Search
forLearn
5 / 13 resultslearn Metformin
diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Minoxidil
An essential vasodilator with some anti-androgenic effects, has excellent safety record
learn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
Research
5 / 1000+ results
research A Simple Decision Tree for Identifying Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation
The decision tree can predict drug absorption issues with good accuracy but needs more validation and adjustments for other factors.
research Pre-Clinical In-Vitro Assays for High Throughput Screening of Drug Candidates for Protection and Restoration of Immune Privilege in Alopecia Areata
The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
research Drug Repurposing: A Promising Approach for Patients With Angina and Non-Obstructive Coronary Artery Disease (ANOCA)
Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
research Drug Repurposing Against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study
Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
research Study of Long-Term 15-Day Imiquimod Treatment and Drug Intervention in Localized Psoriasiform Dermatitis Model
Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.
Community Join
5 / 1000+ resultscommunity We should actually be hopeful for these recent new developments
AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community How many years can we expect PP405 to be on the market
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
community Petition: Make PP405 available tomorrow instead of 2030
PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.